Navigation Links
Oramed Submits Pre-IND Package to FDA for ORMD-0901 (oral exenatide), an Oral GLP-1 Analog for the Treatment of Type 2 Diabetes
Date:9/3/2013

JERUSALEM, September 3, 2013 /PRNewswire/ --

Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that it has submitted a pre-Investigational New Drug (pre-IND) package to the U.S. Food and Drug Administration (FDA) for ORMD-0901, an orally administered exenatide capsule.  Oramed's pre-IND package submission follows its recently announced meeting request letter submitted to the FDA.

The submitted pre-IND package provides the FDA with information on Oramed's ORMD-0901 research conducted to-date, as well as a clinical trial outline for a proposed U.S. clinical trial. The FDA's response to the pre-IND package will serve as a guide to the Company for product development and preparation of a full IND application.  

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines currently delivered via injection. Established in 2006, Oramed's technology is based on over 30 years of research by top research scientists at Jerusalem's Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801) currently initiating Phase 2 clinical trials on patients with type 2 diabetes (T2DM) under an Investigational New Drug application with the U.S. Food and Drug Administration, and with its oral exenatide capsule (ORMD-0901; a GLP-1 analog), with trials on healthy volunteers (Phase 1b) and T2DM patients (Phase 2a) underway. Oramed is also moving forward with clinical trials of ORMD-0801 for the treatmen
'/>"/>

SOURCE Oramed Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oramed CEO to be Panelist at BIO International Convention Breakout Session on Israel Becoming Biotech Leader
2. Oramed Pharmaceuticals Moves Forward with Investigational New Drug Application for Oral Insulin
3. Bioassociate Announces Initiation of Coverage on Oramed Pharmaceuticals, Inc.
4. Oramed Pharmaceuticals Announces Reverse Stock Split
5. Oramed Pharmaceuticals Granted 2nd Patent in New Zealand; 3rd Patent for Core Technology on Oral Delivery of Proteins
6. Marrone Bio Innovations Submits New Bioherbicide for EPA Registration
7. Janssen Submits Additional Marketing Applications for ZYTIGA® in the U.S. and European Union
8. iBio, Inc. Submits Plan to Satisfy NYSE Amex Continued Listing Standards
9. WellnessFX Launches New Products e-HealthAnswers and Womens Fertility Package
10. XY Precision Positioning Stage Provides Nanometer Incremental Motion in a Small Package: PI introduces Affordable 2-Axis Piezo Positioner, Model P-763
11. FDA/PhUSE Collaboration: Study Data Reviewer’s Guide Work Package v1.1 Available
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... , Jan. 14, 2014  RXi Pharmaceuticals Corporation (OTCQX: ... and commercializing innovative therapies addressing major unmet medical ... received the Notice of Allowance from the United ... self-delivering RNAi compounds (sd-rxRNA®), for the treatment of ...
(Date:1/14/2014)... 2014   Kinaxis ®, provider of RapidResponse ®, a ... operations planning ( S&OP ) service, is proud to be ... will be held at the Hilton San Diego Bayfront, January ... Elisabeth Kaszas , Director of Supply Chain at Amgen, ...
(Date:1/14/2014)... Kerr Corporation, a leading manufacturer of innovative dental products, has ... arch impressions on its dental blog. , Titled ... serves up a list of tips to help dentists best ... David Little as he crafts a porcelain crown using Kerr’s ...
(Date:1/14/2014)... Independent publisher Bitingduck Press, with offices in Altadena ... ideas for 2014 in production and sales of interactive ... high-quality, low-cost, DRM-free ebooks and to use the sales ... first major development will be bookstore sales in local ...
Breaking Biology Technology:RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2Bitingduck Press Looks Forward to 2014 With Multimedia E-books 2
... ULURU Inc. (Amex:,ULU) today announced that it ... Food and Drug Administration (FDA) for Altrazeal(TM) Silver., ... have shown that,superior healing rates in numerous porcine ... dressings. Additionally, in toxicology and,in vitro bacteria inhibition ...
... (DIA) will host two co-located conferences from October 23-24 ... ... Horsham, PA (PRWEB) September 30, 2008 -- ... co-located conferences from October 23-24 in Washington DC. ...
... 30 Cell Therapeutics, Inc.,(CTI) (Nasdaq and MTA: CTIC) ... on October 3, 2008. The investor day will provide ... regulatory milestones,for the Company. Additionally, Alessandro Gianni, M.D., Director ... University of Milan,who has authored over 300 publications will ...
Cached Biology Technology:ULURU Inc. Announces the Filing of a 510k Submission With the FDA for Altrazeal(TM) Silver 2ULURU Inc. Announces the Filing of a 510k Submission With the FDA for Altrazeal(TM) Silver 3DIA Co-located Conference to Examine Outsourcing and Project Management Best Practices 2Cell Therapeutics Provides Details on Investor & Media Day to be Held in Milan, Italy on Friday, October 3, 2008 2
(Date:4/18/2014)... survey of emergency contraceptive pills in Peru found ... either of substandard quality or falsified. Many pills ... the wrong active ingredient. One batch had no ... the fake drugs, researchers at the Georgia Institute ... spectrometry to quickly assess suspected counterfeit drugs and ...
(Date:4/18/2014)... sprout as soon as they,re planted may be good news ... careful. In the wild, a plant whose seeds sprouted at ... More than just an insurance policy against late frosts or ... long-term advantages too: Plants whose seeds put off sprouting ... finds in a team of researchers working at the National ...
(Date:4/17/2014)... Respiratory syncytial virus (RSV) is a leading cause ... in very young and elderly populations. Despite great ... cells through the fusion protein RSV F, which ... that prevent bundle formation limit RSV infection in ... degradation. In this issue of the Journal ...
Breaking Biology News(10 mins):Counterfeit contraceptives found in South America 2Counterfeit contraceptives found in South America 3Plants with dormant seeds give rise to more species 2JCI online ahead of print table of contents for April 17, 2014 2JCI online ahead of print table of contents for April 17, 2014 3JCI online ahead of print table of contents for April 17, 2014 4JCI online ahead of print table of contents for April 17, 2014 5JCI online ahead of print table of contents for April 17, 2014 6
... (SSB) and Adolf Kühner AG ,- Prototype of orbital ... Mai 2009 / b3c newswire / – ExcellGene ... biopharmaceutical industry, expands its product offering with the introduction ... rely on orbital shaking principles for mixing compared ...
... a patient,s healthy tissue as well as eradicating the ... especially invasive and often causing nasty side effects. ... more precise and accurate treatment for cancerous tumours by ... Real-time image-guided radiotherapy, combining radiation treatment with non-invasive MR ...
... Medical College of Georgia nurse researcher is among the first ... funding through the American Recovery and Reinvestment Act of 2009. ... jobs and the research of African-Americans in the Augusta community ... seeks to create or save more than 3.5 million jobs ...
Cached Biology News:ExcellGene SA first company to offer contract manufacturing in 250 Liter OrbShake bioreactor 2ExcellGene SA first company to offer contract manufacturing in 250 Liter OrbShake bioreactor 3MCG researcher among first to receive NIH stimulus funding 2
Troponin I (22B11)...
Microlite 1+ 1x12 Strip assembled, flat bottom; the ideal vessel for low signal luminescent reactions, offering medium binding with enhanced dynamic range, extra high reflectivity and minimal cross t...
Immulon 4 HBX 1x12 Strip, flat bottom; high binding extra surface with special resin and irradiation, offers maximum protein uptake....
... and pressurized syringe holder for any researcher who ... rate Microinjecting Fine microliter delivery ... to any new or existing perfusion rig - ... Connect to house air or a compressor (30 ...
Biology Products: